News About: Pharm. Industry
Getting a job at pharmaceutical gets thinner
October is expected to be the most crucial season for job hunters, as a number of pharmaceutical firms that have recruitment plans like other industries are scheduled to employ new workers in the second half of this y...
New drug pricing plan triggers concerns at hospital bidding market
Debates on the drug prices at the hospital bidding market are expected to occur between drug manufacturers and wholesalers, as the prices of 8,776 drugs out of the total 14,410 listed on the national health insurance ...
AstraZeneca seeking R&D potential in Korea
AstraZeneca (AZ), the world's sixth-largest pharmaceutical company, plans to select six Korean research teams to participate in the sixth Virtual Research Institute (VRI) from September 19 to October 19.
The select...
Executives of listed pharmaceutical firms paid average 202 million won in first half
Executives of 38 listed pharmaceutical firms received an average 202 million won per person in the first half of this year, according to Yakup.com.
It said that Samjin Pharmaceutical topped the first-half wage list...
38 listed pharmaceutical firms pay average monthly salary of 4 million won
A total of 38 listed pharmaceutical companies in Korea paid workers 3.95 million won on average a month in the first half of the year, according to Yakup.com.
Citing the data at the Finance Supervisory Service, Yak...
Korean firms stash cash, hesitate investment
Korean drug makers have piled up bigger cash reserve this year, as they refrained from investing amid negative factors, according to Yakup.com.
The cash equivalent assets of 49 companies listed on KOSPI and KOSDAQ ...
Boryung eying sales of 10 billion won with new drug
Boryung Pharmaceutical Co. says its new drug for hypertension “Kanarb (fimasartan)”, angiotensin II receptor antagonist with a selective AT1 receptor blockade effect, is expected to achieve a 10 billion won in sales w...
Anterogen to sell stem cell treatment
Anterogen, a Korean biotechnology venture, filed an application with the Korea Food and Drug Administration Thursday to market a new drug “Cupistem”, a stem cell treatment for anal fistula in Crohn’s disease.
Crohn...
Downsizing to sweep Korean drugmakers
The domestic pharmaceutical industry is expected to be the next targets for downsizing next year as Retail drug prices are expected to fall about 17 percent on average beginning next year following a set of government...
Discontent mounting over recalled contraceptives
The mislabeling of expiration date in Bayer Korea’s Melian tablets has raised public complaint over drug safety in September 2, but the company’s follow-up action goes unheeded.
According to the recent report of Ya...
